Universal Beteiligungs und Servicegesellschaft mbH Buys 57,639 Shares of Medtronic PLC $MDT

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 3.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,627,614 shares of the medical technology company’s stock after acquiring an additional 57,639 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Medtronic were worth $156,489,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Corundum Trust Company INC acquired a new stake in shares of Medtronic during the 3rd quarter worth approximately $27,000. Lodestone Wealth Management LLC acquired a new stake in shares of Medtronic during the 4th quarter worth approximately $27,000. Board of the Pension Protection Fund acquired a new stake in shares of Medtronic during the 4th quarter worth approximately $29,000. GoalVest Advisory LLC acquired a new stake in shares of Medtronic during the 4th quarter worth approximately $29,000. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the 3rd quarter worth approximately $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

MDT has been the subject of several analyst reports. Robert W. Baird lifted their price target on shares of Medtronic from $92.00 to $93.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Truist Financial decreased their price objective on shares of Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. JPMorgan Chase & Co. decreased their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Daiwa Securities Group decreased their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, February 27th. Finally, Wells Fargo & Company assumed coverage on shares of Medtronic in a report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $109.25.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic led a $100M financing round and signed a commercial agreement with Pulnovo Medical, strengthening its respiratory/commercial footprint and signaling targeted investment in growth adjacencies. Medtronic leads $100M investment in Pulnovo Medical
• Positive Sentiment: Medtronic completed the acquisition of CathWorks for $585M, adding the FFRangio® coronary diagnostic platform — a strategic bolt?on to its cardiovascular franchise that should be accretive over time. Medtronic completes acquisition of CathWorks
• Positive Sentiment: Medtronic and GE HealthCare announced a digital integration between Stealth AXiS navigation and bkActiv intraoperative ultrasound, strengthening the neurosurgery product ecosystem and potential cross?sell opportunities. Medtronic And GE HealthCare Tie Neurosurgical Imaging Upgrade To MDT Valuation
• Neutral Sentiment: Industry reports (wearable injectors market) list Medtronic among key players — a long?term tailwind for home/chronic care products but not an immediate earnings driver. Wearable Injectors Market Report 2026
• Neutral Sentiment: Several articles revisit Wall Street analyst recommendations on MDT — analysts are broadly optimistic, which supports medium?term sentiment but has limited impact when investors focus on near?term catalysts. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: News about competitor Intuitive Surgical reporting strong results shows the medtech sector remains active; strong beats elsewhere don’t always lift the whole group, highlighting selective investor flows. Intuitive Surgical Earnings Show Big Beats Don’t Always Spark Stock Rallies
• Negative Sentiment: Market coverage notes Medtronic’s share price moved notably lower today (a larger dip than the broader market), reflecting either profit?taking, rotation away from large medtech names, or short?term reaction to headlines despite the strategic positives above. Medtronic (MDT) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Medtronic Stock Performance

Shares of MDT opened at $82.25 on Wednesday. The firm’s 50 day moving average price is $90.80 and its two-hundred day moving average price is $95.53. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a market cap of $105.60 billion, a P/E ratio of 22.91, a PEG ratio of 2.21 and a beta of 0.75. Medtronic PLC has a twelve month low of $79.93 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts forecast that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date was Friday, March 27th. Medtronic’s payout ratio is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).